CTLA4 and neoplasm: To date, several clinical trials are ongoing investigating personalized neoantigen-based vaccines alone or in combination with anti-PD-1, -PD-L1 and/or -CTLA-4 antibodies in various tumor types, comprising NSCLC (130).